D-NOME Pvt. Ltd. Company Profile

Background

Founded in 2021 and headquartered in Hyderabad, Telangana, India, D-NOME Pvt. Ltd. is a deep-tech startup specializing in molecular diagnostics. The company's mission is to democratize molecular diagnostics by developing affordable, scalable, and accessible genomics-based solutions. By leveraging innovative reagent technologies, D-NOME aims to address global challenges such as infectious diseases and antimicrobial resistance, thereby making a significant impact in the healthcare and life sciences sectors.

Key Strategic Focus

D-NOME's strategic focus centers on revolutionizing molecular diagnostics through its proprietary D-LAMP platform technology. This technology enables room-temperature (37°C) RT-PCR, eliminating the need for specialized RT-PCR machines and reducing operational costs for diagnostic laboratories. The company's core objectives include:

Developing affordable and scalable PCR and genomics solutions.

Enhancing diagnostic accuracy and turnaround times.

Expanding applications into adjacent markets such as livestock screening, veterinary diagnostics, and agricultural molecular testing.

By focusing on these areas, D-NOME targets a rapidly growing $40 billion screening and diagnostics market, positioning itself as a key player in the biotechnology industry.

Financials and Funding

Since its inception, D-NOME has secured a total funding of $1.5 million. The most recent funding round, a seed round completed on January 26, 2023, raised $1.5 million from investors including Ankur Capital and Campus Fund. The capital is intended to support research and development, product launch, and expansion efforts.

Pipeline Development

D-NOME's primary product under development is the D-LAMP platform, a room-temperature RT-PCR technology designed to simplify and expedite molecular diagnostics. The platform is currently undergoing validation and is expected to be launched in the near future. Future milestones include expanding the platform's applications to point-of-care testing and entering new markets such as veterinary diagnostics and agriculture.

Technological Platform and Innovation

D-NOME's innovation is anchored in its proprietary D-LAMP technology, which offers:

Room-Temperature RT-PCR: Enables molecular diagnostics at 37°C, removing the need for specialized equipment.

One-Step Protocol: Simplifies the diagnostic process, reducing the requirement for skilled technicians.

Cost Efficiency: Reduces operational costs by up to 10 times and delivers results five times faster compared to traditional methods.

This technology is based on advanced molecular tools and synthetic biology, positioning D-NOME as a leader in innovative diagnostic solutions.

Leadership Team

Divya Sriram, Ph.D. – Co-Founder and Chief Executive Officer

Ph.D. in Cancer Biology.

Expertise in innovating infectious disease diagnostics using molecular biology.

Leads the company's strategic vision and operations.

Sujoy Deb, Ph.D. – Co-Founder and Chief Technology Officer

Expert in advanced molecular biology and genomics.

Oversees the development and implementation of D-NOME's technological innovations.

Competitor Profile

Market Insights and Dynamics

The molecular diagnostics market is experiencing significant growth, driven by the increasing prevalence of infectious diseases and the demand for rapid, accurate diagnostic solutions. The market is projected to reach $40 billion, with a compound annual growth rate (CAGR) of 15%.

Competitor Analysis

D-NOME operates in a competitive landscape with several notable companies:

Mapmygenome: Based in Hyderabad, India, Mapmygenome offers personal genomics and diagnostic services, focusing on predictive risk assessment and personalized health solutions.

Sherlock Biosciences: A U.S.-based company specializing in CRISPR-based diagnostic tools, providing rapid and accurate detection of various diseases.

Mobidiag: Headquartered in Finland, Mobidiag develops and markets molecular diagnostic solutions for infectious diseases, emphasizing rapid and multiplex testing.

These competitors focus on various aspects of molecular diagnostics, including personal genomics, CRISPR-based diagnostics, and multiplex testing, contributing to the dynamic and rapidly evolving market.

Strategic Collaborations and Partnerships

D-NOME has established significant collaborations to bolster its market position and innovation capacity:

Entrepreneur First: Received pre-seed investment from this London-based investor, supporting early-stage development.

BIRAC – BIG Grant: Secured funding from the Biotechnology Industry Research Assistance Council, facilitating research and development initiatives.

Incubation Centers: Engaged with premier biotech incubation centers such as AIC-CCMB, C-CAMP, and IKP, providing access to resources and mentorship.

These partnerships enhance D-NOME's capabilities in research, development, and market penetration.